Habitat escalated adaptive therapy (HEAT): A phase 2 trial utilizing radiomic habitatdirected and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response (FPR≥95%) from RT is associated with improved patient outcome.